2012
Erratum: Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonb therapy in multiple sclerosis
Vosslamber S, van der Voort L, van den Elskamp I, Heijmans R, Aubin C, Uitdehaag B, Crusius J, van der Pouw Kraan T, Comabella M, Montalban X, Hafler D, De Jager P, Killestein J, Polman C, Verweij C. Erratum: Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonb therapy in multiple sclerosis. Genes & Immunity 2012, 13: 443-443. DOI: 10.1038/gene.2012.18.Peer-Reviewed Original Research
2011
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis
Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der PouwKraan T, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis. Genes & Immunity 2011, 12: 466-472. PMID: 21471993, DOI: 10.1038/gene.2011.18.Peer-Reviewed Original ResearchConceptsRelapsing-remitting multiple sclerosisNon-responder statusInterferon regulatory factor 5IFNβ treatmentMultiple sclerosisT2 lesionsClinical outcomesMore magnetic resonance imagingMore T2 lesionsStart of therapyGene variantsInterferon-β TherapyIFN response genesRegulatory factor 5Poor pharmacological responseMagnetic resonance imagingIFNβ therapyClinical responseFirst relapseIndependent cohortPharmacological responseClinical relevanceG allelePatientsResonance imaging